Sequelae of hypergastrinemia due to long-term administration of proton pump inhibitors and its management
- VernacularTitle:长期使用质子泵抑制剂所致高胃泌素血症及其对策
- Author:
Jian SHEN
;
Jianxin WU
;
Dingguo LI
- Publication Type:Journal Article
- Keywords:
proton pump inhibitor;
hypergastrinemia;
gastrointestinal neoplasms
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2004;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Proton pump inhibitor (PPI) is considered as the standard treatment for acid-related disorders. However, its long-term use, especially in patients with gastroesophageal reflux disease, would cause potential risks, such as hypergastrinemia along with reduced gastric acidity, hyperplasia of enterochromaffin cells (ECL), gastric neoplasms, rebound gastric acid hypersecretion when PPI treatment is stopped, increased oxyntic gastritis in patients with H. pylori infection, and the possible stimulation of growth of non-gastric tumours due to hypergastrinaemia. Each of these trends has led to numerous studies and evaluations on the potential risk-benefit ratio of the long-term use of PPIs, and countermeasures are being proposed for these problems.
